Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 171.16B |
| Revenue (ttm) | 46.87B |
| Net Income (ttm) | 10.82B |
| Shares Out | 1.90B |
| EPS (ttm) | 5.32 |
| PE Ratio | 16.96 |
| Forward PE | 13.08 |
| Dividend | 3.50 (3.94%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 3,927,367 |
| Average Volume | 5,155,648 |
| Open | 89.22 |
| Previous Close | 88.74 |
| Day's Range | 88.87 - 90.39 |
| 52-Week Range | 81.10 - 102.72 |
| Beta | 0.55 |
| RSI | 43.58 |
| Earnings Date | Apr 29, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump says US pharma tariffs coming in not-too-distant future
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Inflation Might Be Easing But Tech Outlook Still Choppy, Analysts Warn
According to data released Thursday by the Bureau of Labor Statistics, the annual inflation rate fell to 2.4% in March, the lowest level in six months, down from 2.8% in February and below economist e...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Novartis
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
Novartis AG (NYSE: NVS) on Thursday unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. over the next five years . The move is part of ...
Swiss drugmaker Novartis to invest $23bn in US manufacturing and R&D
Pharma group builds out American supply chains as part of preparations for potential US tariffs
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2183695394-90b515c0e521476d8529ed23a56b318f.jpg)
Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs
Swiss pharmaceutical giant Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities, as drugmakers brace for potential tariffs from the Trump administration.
Novartis is reportedly eyeing $23B investment in U.S.
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats
Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administ...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
With U.S. President Donald Trump’s tariffs , HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory uncertai...
Novartis After Sandoz: The Business Without Generics
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE: NVS) Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A...
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.
Novartis gets FDA accelerated approval for kidney disease treatment
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed Vanra...